Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Janvier 2024 - 2:00PM
Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it
will present at the 42nd Annual J.P. Morgan Healthcare Conference
at 8:15 AM PT (11:15 AM EST) on Wednesday, January 10, 2024. Live
audio of the event can be accessed by visiting the “Events” page of
the company’s website at investor.pacira.com. A replay of the
webcast will also be available for two weeks following the event.
About Pacira
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to
providing a non-opioid option to as many patients as possible to
redefine the role of opioids as rescue therapy only. The company is
also developing innovative interventions to address debilitating
conditions involving the sympathetic nervous system, such as
cardiac electrical storm, chronic pain, and spasticity. Pacira has
three commercial-stage non-opioid treatments:
EXPAREL® (bupivacaine liposome injectable suspension), a
long-acting local analgesic currently approved for infiltration,
fascial plane block, and as an interscalene brachial plexus nerve
block for postsurgical pain management;
ZILRETTA® (triamcinolone acetonide extended-release injectable
suspension), an extended-release, intra-articular injection
indicated for the management of osteoarthritis knee pain; and
ioveraº®, a novel, handheld device for delivering immediate,
long-acting, drug-free pain control using precise, controlled doses
of cold temperature to a targeted nerve. To learn more about
Pacira, including the corporate mission to reduce overreliance on
opioids, visit www.pacira.com.
Company Contact:
Pacira BioSciences, Inc.
Christian Pedetti
(973) 254-4387
Christian.pedetti@pacira.com
Pacira BioSciences (NASDAQ:PCRX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Pacira BioSciences (NASDAQ:PCRX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024